Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. (Record no. 75376)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05945cam a2200421 4500 |
| 001 - CONTROL NUMBER | |
| control field | NMDX5861 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 120401t2008 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 13596535 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Stoher, W. |
| 240 ## - UNIFORM TITLE | |
| Uniform title | <a href="Antiviral therapy.">Antiviral therapy.</a> |
| 245 ## - TITLE STATEMENT | |
| Title | Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Date of publication, distribution, etc. | 2008 |
| 500 ## - GENERAL NOTE | |
| General note | NMUH Staff Publications |
| 500 ## - GENERAL NOTE | |
| General note | 13 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | <div><h4>BACKGROUND: </h4><p>The aim of this study was to examine <span class="highlight" style="background-color:">factors</span> <span class="highlight" style="background-color:">influencing</span> <span class="highlight" style="background-color:">plasma</span> <span class="highlight" style="background-color:">concentration</span> of <span class="highlight" style="background-color:">efavirenz</span> and <span class="highlight" style="background-color:">nevirapine</span>.</p><h4>METHODS: </h4><p>Data from the Liverpool Therapeutic Drug Monitoring (TDM) registry were linked with the UK Collaborative HIV Cohort (CHIC) Study. For each patient, the first measurement of <span class="highlight" style="background-color:">efavirenz</span> (600 or 800 mg/day) or <span class="highlight" style="background-color:">nevirapine</span> (400 mg/day) <span class="highlight" style="background-color:">plasma</span> <span class="highlight" style="background-color:">concentration</span> was included. Linear regression was used to evaluate the association of dose, gender, age, <span class="highlight" style="background-color:">weight</span>, <span class="highlight" style="background-color:">ethnicity</span> and concomitant antiretroviral drugs or rifampicin with log-transformed drug <span class="highlight" style="background-color:">concentration</span>, adjusted for time since last intake.</p><h4>RESULTS: </h4><p>Data from 339 patients on <span class="highlight" style="background-color:">efavirenz</span> (34% black, 17% rifampicin) and 179 on <span class="highlight" style="background-color:">nevirapine</span> (27% black, 6% rifampicin) were included. Multivariable models revealed the following predictors for <span class="highlight" style="background-color:">efavirenz</span> <span class="highlight" style="background-color:">concentration</span>: black <span class="highlight" style="background-color:">ethnicity</span> (59% higher; P&lt;0.001), <span class="highlight" style="background-color:">weight</span> (10% lower per additional 10 kg; P=0.002), 800 mg/day (52% higher; P=0.027), rifampicin (35% lower; P=0.039), and zidovudine (25% lower; P=0.010). Notably, without adjustment for other <span class="highlight" style="background-color:">factors</span>, patients on rifampicin had 48% higher <span class="highlight" style="background-color:">efavirenz</span> <span class="highlight" style="background-color:">concentration</span>, as these patients were mostly black and on 800 mg/day. For <span class="highlight" style="background-color:">nevirapine</span> the predictors were black <span class="highlight" style="background-color:">ethnicity</span> (39% higher; P=0.002), rifampicin (40% lower; P=0.002), protease inhibitor (28% higher; P=0.008) and tenofovir (22% higher; P=0.024).</p><h4>CONCLUSIONS: </h4><p>We observed clear associations between <span class="highlight" style="background-color:">ethnicity</span> and concentrations of <span class="highlight" style="background-color:">nevirapine</span> and <span class="highlight" style="background-color:">efavirenz</span>. Our analyses confirm that concomitant rifampicin substantially decreases <span class="highlight" style="background-color:">concentration</span> of both <span class="highlight" style="background-color:">efavirenz</span> and <span class="highlight" style="background-color:">nevirapine</span>; however, for <span class="highlight" style="background-color:">efavirenz</span> this <span class="highlight" style="background-color:">effect</span> was more than counterbalanced by the <span class="highlight" style="background-color:">effect</span> of <span class="highlight" style="background-color:">ethnicity</span> and increased <span class="highlight" style="background-color:">efavirenz</span> dose. There was also an additional impact of <span class="highlight" style="background-color:">weight</span>, which should be considered when determining optimal dosage. Other associations from our analysis (between tenofovir or protease inhibitor and <span class="highlight" style="background-color:">nevirapine</span>, and zidovudine and <span class="highlight" style="background-color:">efavirenz</span>), require confirmation in formal pharmacokinetic studies.</p></div> |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Back, D. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dunn, D. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sabin, C. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Winston, A. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gilson, R. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pillay, D. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hill, T. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ainsworth, J. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pozniak, A. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leen, C. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bansi, L. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fisher, M. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Orkin, C. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Anderson, J. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Johnson, M. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Easterbrook, P. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gibbons, S. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Khoo, S. |
| 710 ## - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | UK CHIC Study |
| 710 ## - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | Liverpool TDM Database |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://www.ncbi.nlm.nih.gov/pubmed/18771051">http://www.ncbi.nlm.nih.gov/pubmed/18771051</a> |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://ferriman.wufoo.com/forms/r7x3a7/">http://ferriman.wufoo.com/forms/r7x3a7/</a> |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection code | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Staff publications for NMDX | Ferriman information and Library Service (North Middlesex) | Ferriman information and Library Service (North Middlesex) | Shelves | 07/06/2022 | 07/06/2022 | 07/06/2022 | Book |